Retina Care and Research

Retina Care and Research was paid $205K by Medicaid between Oct 2023 and Nov 2024, across 7 billing codes. Its largest line is J2777, Injection, faricimab-svoa, 0.1 mg — 68% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2023	156	$4K
2024incomplete	1,406	$202K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J2777	Injection, faricimab-svoa, 0.1 mg	68%	146	123	$140K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	12%	36	31	$25K
67028	Intravitreal injection of a pharmacologic agent	10%	457	370	$21K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	4.4%	206	172	$9K
92134		4.2%	598	489	$9K
92020		<1%	103	88	$1K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	<1%	16	14	$598.77

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKARTH, PETER (OWNER)